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ABSTRACT 
Background: Substance use may increase the risk of non-adherence to 
antipsychotics, resulting in negative outcomes in patients with psychosis.  
Aims: To quantitatively summarize evidence regarding the effect of cannabis use, 
the most commonly used illicit drug amongst those with psychosis, on adherence to 
antipsychotic medication.  
Method: Studies were identified through a systematic database search. Adopting 
random-effects models, pooled odds ratios (OR) for risk of non-adherence to 
antipsychotic medications were calculated comparing: cannabis-users at baseline vs 
non-users at baseline; non users vs continued cannabis users at follow-up; non-
users vs former users at follow-up; former users vs current users.  
Results: 15 observational studies (n=3678) were included. Increased risk of non-
adherence was observed for cannabis users as compared to non-users (OR=2.46, 
n=3055). At follow-up, increased risk of non-adherence was observed for current 
users as compared to non-users (OR=5.79, n=175) and former users (OR=5.5, 
n=192), while there was no difference between former users and non-users 
(OR=1.12, n=187).  
Conclusions: Cannabis use increases the risk of non-adherence and quitting 
cannabis use may help adherence to antipsychotics. Thus, cannabis use may 
represent a potential target for intervention to improve medication adherence in 
those with psychosis.  
Declaration of interest: None.  
 
INTRODUCTION 
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Antipsychotic medications play an essential role in the treatment of psychosis (Sendt 
et al., 2014), but their effectiveness is often hindered by poor adherence (Keith & 
Kane, 2003). Reviews report mean non-adherence rates between 27% and 49.5% 
among patients with psychosis (Cramer & Rosenheck, 1988; Lacro et al., 2002; 
Nosè et al., 2003), while they may be up to 63% in first-episode psychosis (FEP) 
samples (Mojtabai et al., 2002; Mutsatsa et al., 2003). Non-adherence is associated 
with negative outcomes such as greater risk of relapse, hospitalization and suicide 
(Higashi et al., 2013). Although predictors of non-adherence have been identified 
(Sendt et al., 2014), they are not always easily amenable to intervention. For 
instance, illness-related factors such as cognitive deficit or lack of insight (Reed et 
al., 2002; Sharma & Antonova, 2003; Buckley et al., 2007) represent a feature rather 
than a comorbidity of psychosis (Buckley et al., 2007) and may be inextricably and 
circularly linked to non-adherence. Similarly, reduction of side-effects may enhance 
adherence (Colom et al., 2005), but this may often be reached through a trade-off 
between the desired level of response and a tolerable level of side-effects to ensure 
the most optimal adherence in a given individual. 
In contrast, one of the most consistently reported risk-factors for non-adherence 
(Fenton et al., 1997; Kampman & Lehtien, 1999; Green, 2006; Buckley, 2007), which 
may also potentially be amenable to intervention (Grech et al., 2005; Addington & 
Addington, 2007; Conrod et al., 2010), is drug use. Cannabis is the most frequently 
used illicit drug worldwide (Global Drug Survey, 2014), especially in those with 
psychosis (Green et al., 2005; Addington & Addington, 2007), with prevalence 
estimates of 16-23% for current and 27-42.1% for lifetime use (Koskinen et al., 
2010). These may be as high as 10-18% for current and 46.9-66% for lifetime use in 
FEP patients (Foti et al., 2010; Van Dijk et al., 2012). Cannabis use is also 
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associated with increased risk of psychosis, increased symptom severity (Moore et 
al., 2007), earlier onset (Large et al., 2011) and more relapses and hospitalizations 
(Zammit et al., 2008; Schoeler et al., 2015), suggesting the importance of this 
predictor of non-adherence in those with psychosis. 
Despite the prevalence and impact of cannabis use, to our knowledge no meta-
analysis has as yet estimated the magnitude of its effect on medication non-
adherence. Only one systematic-review (Zammit et al., 2008) has been published on 
the topic, but it included only three studies providing inconsistent evidence (Zammit 
et al., 2008). Herein, we attempt to estimate the magnitude of the association 
between cannabis use and medication non-adherence in those with psychosis, and 
we assess the reporting strength of the available evidence on the topic. In line with 
previous studies, we control for duration of follow-up (Cramer & Rosenheck, 198; 
Lacro et al., 2002; Miller et al., 2009), age (Gonzalez-Pinto et al., 2006; Addington & 
Addington, 2007; Castberg et al., 2009), gender (Castberg et al., 2009) and baseline 
illness-severity (Zammit et al., 2008). We compare the differential effects of cannabis 
use on adherence between: 1) FEP and non-FEP patients, that show higher rates of 
cannabis use (Foti et al., 2010; Van Dijk et al., 2012) and non-adherence (Mojtabai et 
al., 2002; Mutsatsa et al., 2003); and 2) affective and non-affective patients, in order 
to obtain data relative to more homogeneous diagnostic groups.  
 
METHODS 
 
Literature search and selection procedures 
We applied the Meta-analysis of Observational Studies in Epidemiology (MOOSE) 
guidelines for systematic reviews and meta-analyses of observational studies 
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(Stroup et al., 2000). The final systematic-search was performed on 27/04/2015 
through OVID in 4 databases: EMBASE (1974-2015, week 17); Ovid MEDLINE(R) 
In-Process and Other Non-Indexed Citations (1946 to Present); Journals@Ovid; 
PsycINFO (1806-February 2015). The search, limited to human studies, was run 
through titles (ti) and abstracts (ab). Search terms were grouped in 3 categories: 1) 
DIAGNOSIS: psychosis; psychot*; schizophren*; schizoaff* 2) ILLICIT 
SUBSTANCES: cannabi*; drug-use; drug-abuse; drug-misuse; substance-use; 
substance-abuse; substance-misuse 3) ADHERENCE: adheren*; complian*. The 
Boolean Operator “OR” was adopted to separate within-category terms, while “AND” 
was used to combine the three categories.  
To find further relevant publications, reference lists were screened from included 
papers and other reviews on drug use and adherence. Authors were contacted for 
clarifications and unpublished data. The PRISMA flowchart presented in Figure 1 
shows the selection procedure followed to identify relevant studies, with numbers 
and reasons for exclusion. Data extraction followed a systematic process consisting 
in compiling a database (Supplementary methods 1) with the variables of interest 
retrieved from the included studies. Study selection and data extraction were 
performed by two authors (EF and EK) and disagreement was resolved by 
consensus. 
 
Selection criteria and outcome measure 
Only published peer-reviewed papers in English reporting original studies satisfying 
the following criteria were considered: 1) studies had to investigate the relationship 
between cannabis use and medication adherence; 2) the majority of the sample had 
to be on antipsychotic medication; 3) participants had to be patients diagnosed with 
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schizophrenia or any psychotic disorder using standardized criteria. If cannabis was 
not the only substance  considered, studies were included only when they specified 
that cannabis was the most frequently used illicit substance, or when analysis was 
done for each substance separately, or when other substance use was controlled 
for. If the presence of psychotic symptoms was unclear, papers were included only 
when the majority of the sample was on antipsychotics. Similarly, if treatment was 
referred to simply as “drug treatment” or “medication”, with no specific reference to 
antipsychotic treatment, studies were included only when the sample comprised 
patients with a diagnosis of schizophrenia, other psychotic disorders or bipolar 
disorder with psychotic symptoms, as such patients are most likely to be treated with 
antipsychotics. Overlapping cohorts were excluded. 
The outcome of interest was non-adherence to antipsychotics, with exclusion of 
studies that did not distinguish between adherence to pharmacological and other 
forms of treatment. 
 
Data analysis 
Studies that provided enough data to estimate odds ratio (OR) for risk of non-
adherence were pooled in a meta-analysis. For the rest, a narrative synthesis of the 
findings will be presented. Statistical analyses were conducted with Review Manager 
5.3 (http://tech.cochrane.org/revman) and with R for meta-regression and Egger’s 
Test. DerSimonian and Laird (1986) random effect models (REM) were adopted, 
assuming variations in true effect-sizes across studies (Borenstein et al., 2011). The 
outcome was dichotomized into 2 categories: good vs poor/non-adherence. OR of 
non-adherence and 95% confidence intervals were used as a measure of effect-size 
due to the categorical nature of the outcome. Except where already reported 
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(Coldham et al., 2002), ORs were calculated employing an online software 
(http://www.campbellcollaboration.org/resources/effect_size_input.php) using 
frequency distributions (Linszen et al., 1994; Martinez-Arevalo et al., 1994; 
Kovasznay et al., 1997; Rehman & Farooq, 2007; Barbeito et al., 2013; Jonsdottir et 
al., 2013). Where frequencies were not available, Chi-square value (Pogge et al., 
2005) or mean difference and SD (Strakowski et al., 2007; Schimmelmann et al., 
2012) were used to calculate Cohen's d and its variance, from which ORs were 
estimated. We compared adherence outcomes between cannabis users and non-
users groups. For studies that reported data on course of cannabis use (Martinez-
Arevalo et al., 1994; Faridi et al., 2012; Schimmelmann et al., 2012; Barbeito et al., 
2013) adherence outcomes were also compared between the following groups: non-
users (i.e. those who were not using cannabis both at baseline and at follow-up) vs 
continued cannabis users at follow-up (i.e. those who were smoking cannabis both at 
baseline and follow-up); non users vs former users at follow-up (i.e. those who were 
smoking cannabis at baseline but quit at follow-up); and former users vs current 
users. 
Further details about analysis are reported in Supplementary Methods 2. 
Heterogeneity was estimated through the I2 statistic (Higgins et al., 2003) and 
publication bias through Funnel plots and the Egger’s Test (Egger et al., 1997). 
Possible confounding variables identified a priori based on the rationale presented 
earlier were controlled for through further statistical analysis. For continuous 
variables, the following confounders were entered in meta-regression: 1) duration of 
follow-up; 2) mean age; 3) gender distribution; 4) age difference between cannabis 
users and non-users; 5) time difference between measurement of cannabis use and 
adherence. 
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For categorical variables, sub-group analyses were performed for: 1) ‘FEP’ only 
samples and ‘Non-FEP/mixed’ samples; 2) ‘Affective’ vs ‘Non-affective’ psychosis 
samples; 3) studies that controlled for baseline illness-severity vs those that did not. 
Due to the heterogeneity of diagnostic groups reported in different studies, those that 
included at least 50% patients with affective psychosis were included within the 
‘Affective’ group for the purpose of ‘Affective’ vs ‘Non-affective’ psychosis sub-group 
analysis and vice-versa. 
Post-hoc sensitivity analysis was also performed excluding two studies (Linszen et 
al., 1994; Coldham et al., 2002) that, unlike the others, assessed both cannabis use 
and adherence at follow-up. Two prospective studies (Martinez-Arevalo et al., 1994; 
Barbeito et al., 2013) reported only data on course of cannabis use (i.e. how many 
participants at follow–up had never used cannabis, were currently using cannabis or 
had quit cannabis since baseline) but how many of these participants were using at 
baseline was not reported. For these studies, we inferred that all those who were 
currently using cannabis at follow-up were also users at baseline, as research shows 
that rates of initiation of cannabis use after onset of psychosis are generally very low 
(Miller et al., 2009). In order to rule out possible confounding effects of such an 
approximation, we performed further sensitivity analyses excluding these two 
studies. Additionally, we restricted the analysis to only samples for which 
antipsychotics represented more than 50% of the total psychopharmacological 
treatment; the focus of the present review being on antipsychotic medication, this 
allowed to account for the fact that pharmacological treatment was mixed in several 
studies. Finally, we performed sensitivity analysis on a restricted sample of studies 
rated at least 8 in reporting strength. 
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Assessment of reporting strength 
In keeping with previous systematic reviews (McGrath et al., 2004) and meta-
analyses (Penttila et al., 2014) of psychosis epidemiology, we evaluated the 
reporting strength and characteristics of the included studies with an assessment 
tool (Supplementary Methods 3) employed in a previous related review by Beards 
and colleagues (2013). We adapted this tool to suit the specific focus of the present 
meta-analysis in the absence of a standard tool that was fit for purpose (see 
Supplementary Methods 3). Ratings were obtained by adding scores on a 3-point-
scale (0 to 2) on each item, and a final score (poor = 0-4; moderate = 5-9; good = 10-
14) was assigned to each study.  
 
RESULTS 
 
Results of search 
A final list of 15 manuscripts (Linszen et al., 1994; Martinez-Arevalo et al., 1994; 
Kovasznay et al., 1997; Coldham et al., 2002; Pogge et al., 2005; Perkins et al., 
2006; deHaan et al., 2007; Rehman & Farooq, 2007; Strakowsky et al., 2007; Miller 
et al., 2009; Gonzalez-Pinto et al., 2010; Faridi et al., 2012; Schimmelmann et al., 
2012; Barbeito et al., 2013; Jonsdottir et al., 2013) reporting on 3678 patients, were 
considered for the systematic-review. Of these, those that provided sufficient data for 
effect-size estimation were (Linszen et al., 1994; Martinez-Arevalo et al., 1994; 
Kovasznay et al., 1997; Coldham et al., 2002; Pogge et al., 2005; Rehman & Farooq, 
2007; Strakowsky et al., 2007; Gonzalez-Pinto et al., 2010; Schimmelmann et al., 
2012; Barbeito et al., 2013; Jonsdottir et al., 2013) for cannabis users vs non users 
(n=3055 patients); 3 (Martinez-Arevalo et al., 1994; Schimmelmann et al., 2012; 
10 
 
Barbeito et al., 2013) each for non-users vs current users (n=175) and non-users vs 
former users (n=187) and 4 (Martinez-Arevalo et al., 1994; Faridi et al,., 2012; 
Schimmelmann et al., 2012; Barbeito et al., 2013) for former users vs current users 
(n=192). Further details are presented in Supplementary Results 1. 
 
Insert figure 1 here 
Fig. 1 Literature search and selection of the studies, adapted from the PRISMA 
(Preferred Reporting Items for Systematic Reviews and Meta-Analyses) 
flowchart, www.prisma-statement.org 
 
Study characteristics 
Table 1 shows the main characteristics of all of the 15 studies identified through 
systematic search. The following section presents summary characteristics for the 11 
studies included in the meta-analysis (cannabis users vs non users), while data 
referring to the whole sample of 15 studies is reported as part of Supplementary 
Results 2.  The included 11 studies reported data from 11 different cohorts from 
across the world. Males represented 48.7% of the sample with a mean age of 36.8 
years. This was significantly influenced by data from a single study reporting on the 
largest sample (Gonzalez-Pinto et al., 2010) (n=1831, mean age=45 years), while 
the remaining studies included patients with age ranging from 15 to 30 years. As for 
diagnoses,4 studies included only schizophrenia-spectrum diagnoses, 2 only Bipolar 
I diagnoses, while the others were mixed. The schizophrenia-spectrum disorder 
group included 25.7% of the pooled sample, while 2.1% fell into the other-psychosis 
group, and72.2%) into the Bipolar and other affective disorders group. Within the 
latter category, 48.5% had psychotic symptoms, while for the rest, the presence of 
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psychotic symptoms was not specified. Five studies included only FEP patients early 
in the course of their illness, while samples were mixed in the other studies. The 
majority of the studies were observational (k =11), longitudinal (k=11) and 
prospective (k=6), with follow-up periods ranging from 6 months to 8 years (mean 
=2.3 years). 
 
Table 1: Characteristics of the samples of the included studies 
Insert Table 1 here 
 
Study reporting strength and assessment methods 
No study was excluded on the basis of the assessment of reporting strength though 
separate analysis was carried out for studies having a reporting strength rating of at 
least 8, as part of sensitivity analyses. The following section reports data referred to 
the 11 studies included in the quantitative analysis, while those for the whole sample 
of 15 studies are reported in Supplementary Results 3. Reporting strength 
(Supplementary Results 3) was on average moderate (mean =8) A summary 
description of the assessment methods used in the included study, with a strength 
score, is presented in Supplementary Results 4. Five studies for cannabis and Five 
for adherence gathered data through either only self-reports or only clinical ratings, 
and only 1 study for cannabis and none for adherence used objective measures. 
Only 2 and 3 studies adopted a combination of sources to assess cannabis use and 
adherence respectively. However, it is important to note that most studies (6 for 
adherence and 6 for cannabis) assessed variables at multiple time-points. 
 
Effect of cannabis use on adherence to antipsychotics  
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Summary results from each study are summarized in Table 2, together with the 
frequencies for cannabis use and non-adherence data, where available. 
Outcome measures varied according to the different definitions and cut-off points for 
non-adherence (Supplementary Results 4). Nine studies (Martinez-Arevalo et al., 
1994; Kovasznay et al., 1997; Pogge et al., 2005; Perkins et al., 2006; Miller et al., 
2009; Gonzalez-Pinto et al., 2010; Faridi et al., 2012; Schimmelmann et al., 2012; 
Barbeito et al., 2013) dichotomized the outcome into good vs poor/non-adherence. 
Six studies (Linszen at al., 1994; Coldham et al., 2002; deHaan et al., 2007; Rehman 
& Farooq, 2007; Strakowski et al., 2007; Jonsdottir et al., 2013) included additional 
categories to reflect intermediate levels of adherence, but 3 of them (Linszen et al., 
1994; Coldham et al., 2002; Strakowski et al., 2007) performed comparisons only 
between the two extreme categories. Two studies (Faridi et al., 2012; Barbeito et al., 
2013) also assessed course of adherence, and 1 study (Rehman & Farooq, 2007) 
assessed the number of relapses preceded by poor adherence. In terms of 
definitions, 9 studies (Linszen et al., 1994; Martinez-Arevalo et al., 1994; deHaan et 
al., 2007; Rehman & Farooq, 2007; Strakowski et al., 2007; Miller et al., 2009; 
Gonzalez-Pinto et al., 2010; Faridi et al., 2012; Jonsdottir et al., 2013) defined non-
adherence as “taking medications as prescribed less than x% of the time” (usually 
75-80%); 3 studies (Coldham et al., 2002; Perkins et al., 2006; Schimmelmann et al., 
2012) defined non-adherence as “failing to take medications for longer than 1 week”; 
2 studies (Kovasznay et al., 1997; Pogge et al., 2005) adopted simple yes/no criteria 
(e.g. participant had/did not have adequate adherence during follow up) and 1 study 
(Schimmelmann et al., 2012) based its ratings on yes/no questions (e.g.“Do you 
sometimes forget to take your medicines?”). 
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With reference to the 11 studies included in the meta-analysis, prevalence of 
cannabis use was calculated on the sample of studies that reported it. Prevalence of 
lifetime cannabis use was 18.9% as reported by 4 studies; prevalence of baseline 
cannabis use was 13.9% as reported by 8 studies; and prevalence of current or 
follow-up cannabis use was 6.2% as reported by 4 studies. However, prevalence 
was higher (54.3, 39.125.1% for lifetime, baseline and follow-up use respectively) on 
excluding the study by Gonzalez-Pinto et al. (2010) which reported very low rates of 
comorbid cannabis use, and also when only FEP samples were considered (52.8, 
44.9, 25.8% for lifetime, baseline and follow-up use respectively). Prevalence rates 
of non-adherence at follow-up were 28.9% for the whole sample and 34.3% for the 
FEP sample. Cannabis use and non-adherence data for the larger sample of 15 
studies included in the systematic review are presented in Supplementary results 2. 
 
Table 2: Cannabis frequencies, adherence frequencies and main findings 
Insert Table 2 here 
 
Results of the meta-analysis of 11 studies (Figure 2) suggest that cannabis use is 
associated with a nearly 150% increase in the risk of non-adherence: a highly 
significant increase in the risk of non-adherence was observed at follow-up for 
cannabis users as compared to non-users (OR=2.46, CI=1.97–3.07, 
p<0.00001).There was no evidence of heterogeneity (I2=0%, p=0.71) and Funnel 
Plots and Egger’s Test (Figure 3) showed no evidence of publication bias (p=0.93). 
Findings remained robust after controlling for confounding through sub-group 
analyses (Supplementary Results 5) and meta-regression (Supplementary Results 
6). No significant sub-group differences were found (p>0.05) and the effect-size 
estimate remained highly significant (p<0.00001) in each of the considered sub-
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groups: 1) FEP (OR=2.22) vs non-FEP (OR=3.01); 2) samples comprised of at least 
50% patients with non-affective psychosis (OR=2.38) vs less than 50% (OR=2.51); 
3) studies that controlled for baseline illness-severity (OR=2.97) vs those that did not 
(OR=2.16). 
None of the following moderators entered in meta-regression (Supplementary 
Results 6) had a significant impact on the model (p>0.05): 1) duration of follow-up; 2) 
mean age; 3) gender distribution; 4) age difference between cannabis users and 
non-users; 5) time difference between measurement of cannabis use and 
adherence. 
When sensitivity analysis was performed, considering only studies that reported the 
effect of cannabis as measured before adherence (baseline or lifetime cannabis) 
rather than at follow-up, the effect remained robust (OR=2.49, CI=1.95–3.18, 
p<0.00001, n=9). No changes were detected also when considering only studies 
rated at least 8 in reporting strength (OR=2.24, CI=1.70-2.97, p<0.00001, n=5) or 
only those in which antipsychotics represented at least 50% of the pharmacological 
treatment (OR=2.55, CI=1.88-3.47, p<0.00001) 
The 11 included studies also reported 9 additional outcomes that mostly 
corroborated those considered for quantitative analysis: positive associations were 
reported between non-adherence and baseline (Coldham et al., 2002; Gonzalez-
Pinto et al., 2010; Barbeito et al., 2013), follow-up (Linszen et al., 1994; Coldham et 
al., 2002; Gonzalez-Pinto et al., 2010; Barbeito et al., 2013) and lifetime (Kovasznay 
et al., 1997; Gonzalez-Pinto et al., 2010) cannabis use, 6 of which reached statistical 
significance (p<0.05). 
As for the 4 studies that were excluded from the quantitative analysis, one (deHaan 
et al., 2007) also reported a significant positive association between baseline 
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cannabis use and non-adherence, although cannabis use did not reach significance 
as a predictor of adherence after adjusting for confounders. Two studies (Perkins et 
al., 2006;Miller et al., 2009) adopted Cox Proportional Hazards considering cannabis 
as a covariate varying over time, and found increased hazards of non-adherence for 
cannabis users, although this relationship was significant in only (Miller et al., 2009) 
of the 2 studies. Results for the 4th study (Faridi et al., 2012) will be reported in 
another section as it is pertinent to course of cannabis use. 
Further outcomes of interest included positive association of cannabis use with 
service disengagement (Miller et al., 2009), study-dropout (Pogge et al., 2005) and 
number of past relapses preceded by poor adherence (Rehman & Farooq, 2007). 
 
Insert figure 2 here 
Figure 2: Forest plot of studies comparing non-users vs cannabis users (REM 
1). 
 
 
Insert figure 3 here  
Figure 3: Regression Test for Funnel Plot Asymmetry and Egger’s test 
model: weighted regression with multiplicative dispersion 
predictor: standard error 
test for funnel plot asymmetry: t = 0.0862, df = 9, p = 0.9332 
 
Effect of course of cannabis use on adherence to antipsychotics  
Results for effect of course of cannabis use are presented in Figure 4. When current 
cannabis users were compared to non-users, a nearly 480% increase in the risk of 
non-adherence was observed, which was highly significant.current usersnon 
users(OR=5.79, CI=2.86–11.76, p<0.00001, I2=0%, p for heterogeneity=0.56, 
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n=175), while comparisons between non users and former users (OR=1.12, 
CI=1.12–2.07, p=0.71, I2=0%, p for heterogeneity=0.37, n=187) and between current 
users and former users (OR=1.81, CI=0.25–13.24, p=0.56, I2=88%, p for 
heterogeneity<0.0001, n=192) were not significant. However, the latter became 
significant (OR=5.5, CI=2.58–11.69, p<0.00001, I2=0%, p for heterogeneity=0.99, 
n=144) suggesting increased risk of non-adherence for current users after exclusion 
of a study (Faridi et al., 2012) with data missing for close to a quarter of the 
participants and only reported this as part of a subgroup analysis, suggesting a 
450% increase in the risk of non-adherence for current users as compared to former 
users. Sensitivity analyses detected no relevant changes after excluding the two 
studies (Martinez-Arevalo et al., 1997; Barbeito et al., 2013) for which current users 
at follow-up were all assumed to have been also cannabis users at baseline  
(OR=2.57, CI=2.03–3,26, p<0.00001). 
Additional analyses are available as Supplementary Results 7. 
One study (Barbeito et al., 2013) also directly examined the relationship between 
course of cannabis use and course of adherence: those in whom adherence 
improved during follow-up were more likely to have been a former or never user as 
compared to those who were cannabis users. 
 
Insert figure 4 here 
 
Figure 4: Forest plots of studies comparing non users (NU) vs current 
cannabis users (CCU), non-users vs former users (FU) and former users vs 
current users at follow-up 
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DISCUSSION 
 
Summary of findings 
To our knowledge, this is the first meta-analysis to estimate the magnitude of the 
effect of cannabis use on adherence to antipsychotics. Results suggest that 
cannabis use increases the risk of non-adherence and that quitting cannabis may 
reduce the risk of non-adherence to antipsychotic medication in patients with 
psychosis (for possible underlying mechanisms see Supplementary discussion). 
Cannabis being the most used illicit drug among patients with psychosis (Addington 
& Addington, 2007), these results are consistent with previous evidence on the 
association between drug use and poor adherence (Sendt et al., 2014). 
Given the longitudinal design of the included samples and the results of sensitivity 
analyses considering only baseline/lifetime cannabis use, cannabis use may be 
regarded as a risk factor that predicts future non-adherence. However, this may also 
reflect the effect of continued cannabis use rather than some long-lasting effect of 
the substance over time. In fact, when current users at follow-up were compared to 
former users (excluding one outlier) an increase in the risk of non-adherence was 
observed while there was no significant difference between former users and non-
users at follow-up, suggesting that quitting cannabis may help improving adherence. 
While results for the comparison between baseline cannabis users and non-users 
appear robust, those on the effect of course of cannabis use are far from definitive. 
Not only did the comparisons non-users vs current users, non-users vs former users 
and former users vs current users at follow-up include only a modest number of 
studies, but they were also quite heterogeneous. For instance, Faridi et al. (2012) 
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found that current users were actually more compliant than former users, in contrast 
with the other 3 studies (Martinez-Arevalo et al., 1994; Schimmelmann et al., 2012; 
Barbeito et al., 2013) that performed the same comparison. However, in this study 
data were missing for close to a quarter of the participants and these results were 
only reported as part of a subgroup analysis. Although the comparison non-users vs 
former users suggested a non-significant increase in non-adherence risk for former 
users (OR=1.12), 2 (Martinez-Arevalo et al., 1994; Barbeito et al., 2013) out of the 3 
studies considered found the opposite effect, i.e., that former users were more 
compliant than non-users. One interpretation is that quitting cannabis may imply high 
levels of commitment and insight and an active approach to managing one’s illness 
that may also lead to enhanced adherence. Further research focusing directly on the 
course of cannabis use and adherence is needed to disentangle the true nature of a 
relationship that appears complex and multifaceted. 
Meta-regression and subgroup analyses suggest that the effect of cannabis use on 
non-adherence was not explained by differences across studies in medication type 
(i.e. proportion on antipsychotics), diagnosis, illness severity at baseline, reporting 
strength, follow-up duration, age, gender distribution and time-lag between 
measurements of cannabis use and adherence. However, the lack of effect of 
potential confounders on meta-regression and sub-group analyses may reflect the 
fact that these tests did not have enough power to detect small differences across 
fairly homogeneous samples (I2=0%).  
 
Methodological issues 
Observational designs are most suited to investigating the association between 
cannabis use and poor adherence as enrollment in a clinical trial may indirectly 
19 
 
improve adherence and hinder generalization to real-life setting by differing from 
routine care (Perkins et al., 2006). However, inclusion of incident cases without 
randomization in observational studies leave open the possibility of confounding 
effect of other predictors of non-adherence: age (Gonzalez-Pinto et al., 2006), 
gender, illness severity (Zammit et al., 2008), insight (Reed et al., 2002), other 
drugs/alcohol use (Sendt et al., 2014), time on antipsychotics, previous non-
adherence and number of relapses (Martinez-Ortega et al., 2012). 
Furthermore, correlational studies do not allow causal inference to be drawn, as it is 
also possible that non-adherence may in turn increase cannabis use. Nonetheless, 
several factors make this less likely. Longitudinal designs adopted by the studies 
included here ensured that the assessment of cannabis use preceded that of 
adherence. Moreover, it can be assumed that, in FEP samples, which were the 
majority, onset of cannabis use preceded the onset of psychopharmacological 
treatment. Finally, since cannabis use tends to decrease rather than commence after 
illness-onset (Miller et al., 2009), non-adherence is less likely to have resulted in a 
large proportion of patients who had never used cannabis to start using it (Miller et 
al., 2009). Another methodological issue was sample-size: only 3 studies included a 
sample of at least 250 participants, which has been estimated (Zammit et al., 2008) 
to be desirable to obtain 80% power to detect an effect of cannabis use on psychotic 
outcome. 
While methodological issues may also have led to errors in the detection of non-
adherence across the sample, this is most likely to have resulted in under- rather 
than over-estimation. It is worth noting that, although selection bias and attrition 
remain an inherent problem with observational, longitudinal, prospective designs, as 
those who refuse to participate or those who drop out are more likely to have been 
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non-adherent (Pogge et al., 2005; deHaan et al., 2007; Jonsdottir et al., 2013)  
studies included here had generally low levels of refusal and attrition. The outcome 
variable was generally dichotomized into adherence/non-adherence in a simplistic 
manner, less reflective of the complexity of the phenomenon in real-life (Julius et al., 
2009), compared to when considered as a continuum. Finally, although 
misrepresentations of complex phenomena such as non-adherence are inevitable as 
no assessment methodology is free from limitations1, only 3 (Martinez-Arevalo et al., 
1994; Miller et al., 2009; Jonsdottir et al., 2013) studies gathered data on adherence 
from at least 2 sources of a different nature, as recommended in a recent review 
(Velligan et al., 2006). Similarly, only 2 (Miller et al., 2009; Barbeito et al., 2013) 
studies did so when assessing cannabis use. Overall, rates and patterns of cannabis 
use and non-adherence, including their greater prevalence in FEP samples, were 
consistent with previous reports (Lacro et al., 2002; Koskinen et al., 2010), 
suggesting that cannabis use and non-adherence were nonetheless fairly-well 
represented. 
 
Limitations 
One limitation of the present meta-analysis was that it was not possible to 
quantitatively pool data from all 15 studies that were identified by the systematic 
search. However, the outcomes reported in these studies were generally in line with 
the pooled results from 11 studies that were included in the meta-analysis. 
The present review aimed at gathering the most extensive evidence for the effect of 
cannabis use on medication non-adherence. Therefore, reporting strength was not 
used as exclusion criteria, but rather to identify issues to be addressed by future 
research. However, sensitivity analyses including only studies rated at least 8 in 
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reporting strength did not detect significant changes in the overall effect-size. 
Several confounders could not be accounted for due to missing data and 
heterogeneity, including differences in assessment methodologies. While this 
hinders coherent interpretation of findings, it also shows that similar results were 
obtained through different methods, decreasing the likelihood of bias inherent to one 
particular methodology. Similarly, the role of further factors associated with both 
cannabis use and non-adherence could not be assessed in the present paper. For 
instance, personality traits as sensation seeking, boredom-susceptibility, disinhibition 
(Liraud & Verdoux, 2001) and impulsivity (Swann et al., 2004) may be at the basis of 
both cannabis use and non-adherence. Baseline illness-severity was accounted for 
only by comparing studies that controlled for it with those that did not. Given the 
heterogeneity of scales adopted to assess it, it was not possible to explore whether 
illness-severity as a continuum had an effect on the model, or whether it differed 
significantly between cannabis users and non-users. A further limitation relates to the 
presence of a substantial proportion (31.73%) of patients for whom the presence or 
absence of psychotic symptoms was not specified. However, such patients were 
distributed across studies in a way that never represented a significant majority, 
except for one study (Gonzalez-Pinto et al., 2010). 
Our focus on adherence to antipsychotic treatment did not allow us to investigate 
other aspects of pharmacological treatment other than adherence (e.g. medication 
resistance, responsiveness and side-effects) and different aspects of adherence, 
(e.g service-disengagement and drop-out) that may also be affected by cannabis 
use. Future research should explore the interaction between cannabis use, service 
disengagement and medication adherence in determining illness outcome, which 
may be complex and multidirectional. Finally, since cannabis use was always 
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dichotomized into use vs non-use, investigating the existence of a dose-response 
effect on adherence was not possible with the present data. 
 
Implications for future research and clinical practice 
The number of studies included in the present meta-analysis is relatively limited 
considering the prevalence of cannabis use in psychosis and the impact of non-
adherence in clinical practice. Therefore, there is an urgent need for further research 
in the area. Bearing in mind the methodological issues highlighted, future research 
needs to adopt longitudinal, prospective designs, possibly including antipsychotic-
naive participants and randomized controls; consider better adjustment for relevant 
confounders, longer follow-up duration and larger samples, multiple means of 
assessment of variables, including objective ones; and employ definitions of non-
adherence that better reflect its complexity, selection procedures and designs that 
minimize bias and attrition and assessments at multiple time-points to better pin-
point changes in cannabis use and adherence. Furthermore, as mentioned before, 
further research is needed to directly investigate the effect of course of cannabis use 
on adherence. 
Finally, studies should investigate how cannabis use and non-adherence interact in 
influencing psychosis outcome. In fact, although previous research has suggested 
that cannabis use has a negative effect on psychosis outcome (Zammit et al., 2008; 
Shoeler et al., 2015), it is not clear to what extent this effect may be mediated by 
non-adherence. This could not be systematically assessed in the present meta-
analysis as most studies adopted non-adherence as the only outcome measure. 
Only two studies among those included (Faridi et al., 2012; Shimmelmann et al., 
2012) directly assessed the interaction between non-adherence and cannabis use on 
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clinical outcomes, with opposite findings. Faridi et al. (2012) found that, while follow-
up symptom severity was not affected by cannabis use, continued cannabis users 
had increased level of symptoms after controlling for medication adherence. On the 
contrary, Shimmelman et al. (2012), reported that medication non-adherence did not 
explain the relationship between continued cannabis use and worse clinical 
outcome. Four other studies (Linszen et al., 1994; Martinez-Arevalo et al., 1994; 
Kovasznay et al., 1997; Rehman & Farooq, 2007) adopted non-adherence and 
cannabis use as predictors of clinical outcomes, and found that both variables were 
associated with each other and independently associated with worse outcome. For 
instance, Rehman & Farooq (2007) reported that cannabis users had increased 
number of relapses and that these were more often preceded by poor drug 
compliance, suggesting that non-adherence may play a role in precipitating relapse 
in cannabis users. However, such correlational findings do not allow us to reach 
conclusion on whether non-adherence is the main reason for the observed 
differences in outcome according to cannabis use. Perhaps the relationship between 
cannabis use, non-adherence and outcome of psychotic illness may be multi-
directional, with symptoms, cannabis use and non-adherence being part of a self-
reinforcing cycle of reciprocal exacerbation (Miller et al., 2009). Nevertheless, this is 
an area that needs systematic investigation in future studies. 
Our findings have important clinical implications. The magnitude of the pooled effect 
suggests that discouraging cannabis use in those with psychosis may result in fairly 
large improvement in adherence and thus better prognosis. This is particularly 
because available evidence suggests that antipsychotic medications have limited 
efficacy at best on psychosis parameters as well as cannabis use parameters in 
24 
 
those patients with psychosis and comorbid cannabis use (Wilson & Bhattacharyya, 
2015).  
Non-adherence is not only difficult to solve (Sendt et al., 2014) but also to detect in 
clinical practice. It is generally identified only after multiple relapses, or 
misinterpreted for lack of medication-efficacy, resulting in continuous and ineffective 
changes in prescriptions (Cramer & Rosenheck, 1998). Results presented here 
suggest that comorbid cannabis use may act as an early warning sign of future non-
adherence and perhaps indicate to clinicians the need to intervene before relapse 
occurs. This may involve appropriate strategies, including for instance an early 
switch to depot medication to prevent the emergence of non-adherence in those at 
risk (Keith & Kane, 2003)  as a result of comorbid cannabis use. 
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